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Available online 6 July 2014Abstract Pluripotent stem cells (PSCs) have indisputable cardiomyogenic potential and therefore have been intensively
investigated as a potential cardiac regenerative therapy. Current directed differentiation protocols are able to produce high
yields of cardiomyocytes from PSCs and studies in small animal models of cardiovascular disease have proven sustained
engraftment and functional efficacy. Therefore, the time is ripe for cardiac regenerative therapies using PSC derivatives to be
tested in large animal models that more closely resemble the hearts of humans. In this review, we discuss the results of our
recent study using human embryonic stem cell derived cardiomyocytes (hESC-CM) in a non-human primate model of ischemic
cardiac injury. Large scale remuscularization, electromechanical coupling and short-term arrhythmias demonstrated by our
hESC-CM grafts are discussed in the context of other studies using adult stem cells for cardiac regeneration.
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Cardiovascular disease is a major cause of morbidity and
mortality world-wide (Lozano et al., 2012). Prognosis of
heart failure patients admitted to hospital is particularly
poor with 5 year mortality approaching 50% (Askoxylakis
et al., 2010; Stewart et al., 2001). While there has been
great progress in recent years in treatment of heart failure
and causative cardiac diseases (Yancy et al., 2013) there
remains an inexorable decline in cardiac function requiring
heart transplantation to avoid death. Unfortunately, de-
mand for donor hearts greatly outstrips supply, such that
N99% of potentially eligible patients are not afforded this
opportunity. Furthermore, co-morbid non-cardiac disease
often precludes recruitment into heart transplantation
programs. It is from this unmet need that enormous interest
in stem cells for myocardial replacement therapy has rapidly
grown. Several cell types including various adult stem cells
(ASCs) and pluripotent stem cells (PSCs) have undergone
intensive investigation in preclinical models. Many ASCs have
also progressed into clinical trials. The first large animal
studies using PSCs for cardiac regeneration are now being
performed, and PSCs are poised to soon enter the clinical
arena for heart repair. This short reviewwill discuss findings of
our recent study using human embryonic stem cell (hESC)
derived cardiomyocytes (CM) in a non-human primate (NHP)
model of ischemic cardiac injury andwill discuss these findings
in the context of the current wider cardiac regenerative field.Importance of large animal models
Although large animal models were used commonly in cardio-
vascular research “back in the day”, in the 1990s there was a
marked shift toward mouse models to exploit their genetic
malleability. Consequently, much of our more recent knowl-
edge of cardiovascular biology, including initial proofs of
concept for novel therapeutics comes from small animals
(predominantly mice or rats). However, significantTable 1 Comparison of heart weight, rate and systolic
pressure between animals used commonly for models of
heart disease (adapted from Gandolfi et al., 2011).
Species Heart weight
(g)
Heart rate
(beat/min)
Systolic pressure
(mm Hg)
Human 360–480 60–90 60–120
Pig 400–500 65–75 70–130
Sheep 240–360 70–80 80–120
Dog 160–420 60–120 120–150
Monkey 37–52 110–140 100–130
Rabbit 9–11 120–300 70–170
Mouse 0.14–0.15 500–600 80–160differences in fundamental cardiac characteristics exist
between mice, rats and humans (Dixon and Spinale, 2009).
Themost obvious differences between these species are the
size of their hearts and their heart rates (Table 1) (Gandolfi et
al., 2011). Accommodating this range of dynamics are multiple
differences at the cellular and molecular level. Differences
occur in myocyte size, contractile filament isoforms, ion
channels and pumps (Ginis et al., 2004; Haghighi et al., 2003;
Rakusan and Nagai, 1994; Stoker et al., 1982; Wehrens et al.,
2000). Therefore, for research aimed at clinical translation,
it is imperative that initial results from rodent studies be
confirmed in a large animal model more closely resembling
the heart of humans. In studies investigating cell therapy for
cardiac regeneration, many different species have been
used including pigs (Bolli et al., 2013; Ellison et al., 2011;
Hatzistergos et al., 2010; Johnston et al., 2009; Kawamura et
al., 2012), dogs (Linke et al., 2005; Perin et al., 2008), sheep
(Grieve et al., 2010; Hou et al., 2012; Menard et al., 2005) and
monkeys (Bel et al., 2010; Blin et al., 2010). Each of these
models has its own advantages and disadvantages which need
to be considered, depending on the specific aims of the studies
(Gandolfi et al., 2011).
Large animal models also allow studies using delivery
methods that will be used for early stage clinical studies.
This is especially important since regulatory bodies will
consider the delivery device as part of the treatment to be
assessed. Therefore safety and toxicity data using the
appropriate delivery method will be required. The most
common delivery methods used clinically for cardiac cell
therapy are 1) trans-epicardial injection into the myocardi-
um using direct visualization of the heart after thoracotomy
(Menasche et al., 2008, 2003; Mocini et al., 2006) and
2) trans-endocardial injection using percutaneous delivery
catheters (Heldman et al., 2013; Hendrikx et al., 2006;
Perin et al., 2004). These are often used in conjunction with
specialized mapping techniques to target areas of the heart
with least electromechanical activity 3) intra-coronary
infusion usually using an over-the-wire angioplasty balloon
(Assmus et al., 2002; Bolli et al., 2013; Janssens et al., 2006;
Makkar et al., 2012). (Intravenous delivery has largely been
abandoned due low efficiency of homing.) Of these methods
the intra-coronary route is the most straightforward and
would allow rapid translation by many interventional cardiol-
ogists well versed with this technique. The limiting factor for
intracoronary delivery is microvascular occlusion, which
makes it difficult to restore the billion or so cardiomyocytes
lost to serious infarctions. Trans-endocardial injections are
more complex, although still reasonably accessible to an
experienced interventional cardiologist or electrophysiolo-
gist. Trans-epicardial injection is the most invasive delivery
approach since it commonly requires thoracotomy, although
thoracoscopic injection using a mini-thoracotomy has also
been utilized to decrease the invasiveness of the procedure
(Ota et al., 2008).
Of these approaches, there is increasing evidence that
intramyocardial injection results in greater cell engraftment.
656 J.J.H. Chong, C.E. MurryThis is particularly true for larger cells (MSC, PSC-CM) that are
less likely to traverse the vascular barrier at intracoronary
injection, compared to, say, bone marrow mononuclear cells.
We recently reported a proof-of-concept study where-
in human embryonic stem cell-derived cardiomyocytes
(hESC-CMs) were transplanted into the infarcted hearts of
non-human primates Chong et al., 2014. In this study, we
elected to use trans-epicardial intramuscular injection of our
hESC-CMs after thoracotomy. During pilot experiments we
found a significant degree of cell “leakage” from the injection
site directly after injection. This was a result of the high
pressures within the left ventricular myocardial wall. There-
fore, we incorporated a small purse-string suture into our cell
delivery technique. The cell injections were made through the
ready-placed suture and the purse string tightened around the
needle immediately after injection. We demonstrated in pilot
studies that this promoted about a 3-fold retention of injectate
within the intra-myocardial wall (Chong et al., 2014). We
realize that this approach may not ultimately be clinically
feasible and further studies utilizing trans-endocardial injec-
tion are planned.Remuscularization of the damaged heart in animal
models
Early studies using skeletal myoblasts for cardiac re-
muscularization have shown that engraftment is possible;
however transdifferentiation of myoblasts to cardiomyocytes is
not (Murry et al., 1996; Reinecke et al., 2002). Based on these
efforts, investigation of ASCs then PSCs as sources of replace-
ment cardiomyocytes gained momentum. Using small animal
models, initial high impact studies suggested that bone marrow
(BM) HSCs could transdifferentiate into cardiomyocytes (Orlic
et al., 2001). In more rigorous follow-up studies, however,
genetic lineage tracing showed that bone marrow stem cells
differentiated into myeloid cells that did not persist in the
infarct; hence marrow-to-myocardium transdifferentiation
does not occur (Balsam et al., 2004; Murry et al., 2004).
Similarly, although initial reports show BM MSCs being able
to generate new myocardium (Shake et al., 2002; Toma et
al., 2002), subsequent studies have failed to demonstrate
significant new donor-derived cadiomyocytes (Dixon et
al., 2009). Therefore, it is becoming increasingly accepted
that the secretion of various factors and cytokines is
responsible for ventricular functional improvements after
delivery of these cell types (Mirotsou et al., 2011, 2007;
Shintani et al., 2009).
Various endogenous cardiac stem cell (CSC) populations
have now been reported to replace damaged myocardium.
Early reports suggested that engraftment of these cells would
lead to robust differentiation and replacement cardiomyocytes
(Beltrami et al., 2003; Smith et al., 2007). However, more
recent studies show that, like bone marrow mononuclear cells
and MSCs, CSCs do not persist long term in the injured heart,
and paracrine mechanisms are the predominant mechanism of
functional improvement (Li et al., 2012; Malliaras et al., 2012).
Indeed, a recent study showed that the leading candidate CSC
population, the cell derived from the heart that expresses the
c-Kit receptor, does not generate new cardiomyocytes during
either normal homeostasis or after infarction (van Berlo et al.,
2014). This suggests that the c-Kit+ cell is not a stem cell forcardiomyocytes. Large animal studies pivotal in the clinical
translational path for CSCs show, at best, low level engraft-
ment of donor cells (Bolli et al., 2013; Johnston et al., 2009).
Consequently, the mechanism of functional improvement in
clinical trials remains unclear (Bolli et al., 2011; Makkar et
al., 2012).
In contrast to ASCs, PSCs possess indisputable potential to
form large numbers of spontaneously contracting cardio-
myocytes (Burridge et al., 2012; Mummery et al., 2012;
Murry and Keller, 2008). Furthermore, small animal studies
have shown that hESC-CM shows long term engraftment in the
infarcted heart (Caspi et al., 2007; Fernandes et al., 2010;
Laflamme et al., 2005; van Laake et al., 2007) with the
cardiomyocyte phenotype being maintained at 3 months after
delivery (Fernandes et al., 2010). In addition to hESC-CM,
cardiovascular progenitors, also derived from hESC, have
shown promising benefits for cardiac regeneration (Bel et al.,
2010; Blin et al., 2010; Song et al., 2010).
Despite the robust findings from these small animal
studies, large animal experiments using PSC derived CM
have been more difficult to accomplish and slower to
complete, compared to similar studies using ASC deriva-
tives. The predominant reason for this has been difficulty
generating sufficient quantities of CM for such experiments.
While efficient methods of undifferentiated hESC propaga-
tion and expansion have been available for some time,
achieving consistently high purity of cardiomyocytes from
resultant differentiation has been more difficult. Early efforts
to enhance cardiomyocyte yields used physical purification
such as via Percoll-centrifugation (Laflamme et al., 2007). This
has proven to be excessively harsh on the treated cells with
a drastic reduction in viable cell yields. Since then other
strategies to purify CM from differentiation have included live
cell sorting for SIPRα+ cells (enriching for CM) (Dubois et al.,
2011) and a novel culture based approach exploiting the
greater resistance to anaerobic metabolism in CM (Tohyama
et al., 2013). In our hands, cell sorting based on SIPRα or
selection in a lactate-rich medium has not proven sufficiently
scalable for large animal studies, so we have focused on
improving our differentiation conditions to the point where we
do not need purification. These efforts have proved fruitful.
Even without enrichment strategies, current directed
differentiation protocols routinely allow the experienced
cell biologist to achieve 70–95% CM purity. Furthermore,
small molecules modulating theWnt/β-Catenin pathway show
promise in replacing expensive and batch-variable cytokines
thereby further improving the reliability and efficient produc-
tion of hESC-CM (Lian et al., 2012).
Another limitation for any potential cell therapy for cardiac
regeneration is low efficiency of donor cell engraftment
(Robey et al., 2008). The success of engraftment is influenced
by the physical retention of cells after delivery, the fraction
that dies after being retained, and the proliferation of the
surviving fraction. It has long been recognized that there is
extensive cell death after transplantation, in part related to
ischemia (cell clumps are inherently avascular) and to anoikis
(death due tomatrix detachment). One strategy developed by
our group is to inhibit cell necrosis and apoptosis via multiple
pathways by using a “pro-survival cocktail” (Laflamme et al.,
2007). Although this cocktail improved survival by several
logs, we estimate that ~90% of the retained cells still die
post-injection. Hence, there is considerable gain in graft size
Figure 1 Human cardiomyocyte grafts within injured monkey hearts. Low power 20× (A) and high power 60× (B) confocal
immunofluorescence microscopy of human embryonic stem cell derived cardiomyocytes delivered into the infarcted monkey heart
and analyzed 14 days after cell delivery. Note the presence of sarcomeric organization and cross-striations present within human
cardiomyocytes although much less organized than the host adult monkey cardiomyocytes. GFP = green fluorescent protein.
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death.
While the pro-survivalcocktail enabled considerable
hESC-CM graft size in rodent and guinea pig (Shiba et al.,
2012) experiments, the cell numbers required for trans-
plantation into hearts of large animals were calculated to
still be at least an order of magnitude greater. The logistics
in coordinating the timing of large scale hESC differentia-
tion and complex large animal experiments are extremely
difficult and potentially wasteful. Therefore a cryopreser-
vation strategy appeared necessary to uncouple the timing
of cell production from cell delivery. Although theoretically
possible that cryogenic procedures could prohibit successful
hESC-CM engraftment, this has not been the case when
directly tested in rodent models (Xu et al., 2011). In our NHP
studies we employed and also tested the ability of
cryopreserved hESC-CM to engraft in an immune incompe-
tent mouse model (Chong et al., 2014). After demonstrating
in mice that engraftment rates of cryopreserved hESC-CM
were comparable to those engrafted directly after cell
culture, we then employed a strategy of cryopreserving
large quantities of hESC-CM after large-scale differentiation
efforts. Therefore, the above advances have paved the way
for a new wave of large animal experiments investigating
the potential of hESC-CM to regenerate the failing/
damaged heart.Remuscularization of the non-human primate heart
As discussed above, relatively few studies have used PSCs to
investigate cardiac regeneration in large animal models.
Rhesus monkeys have been used to study the ability of
allogeneic NHP ESC derived cardiovascular progenitors trans-
plantation to regenerate infarcted hearts, with (Bel et al.,
2010) and without the addition of BM derived MSC (Blin et al.,
2010). Recently, human iPSC derived CM have been used in a
swinemodel of MI investigating whether CM cell-sheets induce
cardiac regeneration (Kawamura et al., 2012). In these studies
however, there were few engrafted cardiomyocytes detected
in the hearts of treated animals.
We sought to use hESC-CMs to generate long term grafts
of human myocardium in the hearts of non-human primates.
Pig-tailed macaques (Macaca nemestrina) were infarcted
percutaneously using a balloon catheter, with 90 min of
ischemia followed by reperfusion. Nine days later, immu-
nosuppression with cyclosporine A, methylprednisolone and
abatacept was commenced and continued until sacrifice. At
2 weeks post-infarction the monkeys were anesthetized and
their hearts exposed via left thoracotomy. Under direct
visualization we injected 1 billion hESC-CM into the peri-infarct
and central ischemic region, using the afore-mentioned purse
string technique. Control animals underwent the same myocar-
dial infarction and had “sham” treatment with intra-myocardial
658 J.J.H. Chong, C.E. Murry
Figure 3 Relative size of human cardiomyocyte grafts in the infarcted rat and monkey hearts. Human embryonic stem cell derived
cardiomyocyte (hESC-CM) grafts in the infarcted rat (A) and monkey (B) hearts. hESC-CM graft is detected by anti-green fluorescent
protein primary antibody with 3,3′-diaminobenzidine detection of secondary antibody (brown). Scale bar = 2.5 mm.
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without cells). Using this model we have shown that clinical
scale production and resulting engraftment (Figs. 1 and 2) in the
NHP infarcted myocardium are possible and reproducible. We
enrolled seven macaques into this study and have shown robust
graft survival at 3 months (the longest time-point examined).
One animal was euthanized prior to cell transplantation due to
arterial thrombosis, with the remaining 6 included in data
analysis. Myocardial infarcts were consistent (2.5–10.4% of LV),
and grafts sizes were large, ranging from 0.7% to 5.3% of the
LV mass (Chong et al., 2014). One monkey had ventricular
fibrillation upon myocardial reperfusion and was successfully
cardioverted. The remainder of the animals tolerated the
procedure well. To our knowledge, this is by a factor of 10-fold
the largest graft of humanmyocardium that has been achieved,
using any animal model and any stem/progenitor cell type. As
an indication of progress in this area, Fig. 3 demonstrates the
relative sizes of our hESC-CM grafts in the infarcted rat and
macaque hearts.
One potential limitation of using PSCs to produce CMs for
heart failure treatment is that the resulting CMs possess an
immature phenotype (Kehat et al., 2001). While this may
actually prove beneficial for graft survival, since fetal cells
are relatively insensitive to hypoxia, the immature pheno-
type may not impart the necessary force generation forFigure 2 Human cardiomyocyte grafts display maturation with ti
cence of microscopy of human embryonic stem cell derived cardiomy
made from grafts analyzed 14 days (A, C and E) or 84 days (B, D and
size and alignment (A–B), increased connexin expression (C–D) an
fluorescent protein. Cx43 = connexin 43.functional cardiac improvement. Furthermore, the imma-
ture calcium handling (Dolnikov et al., 2006; Liu et al.,
2007), slower conduction velocity and residual pacemaking
currents may result in arrhythmogenesis after engraftment.
Interestingly, in our NHP experiments, we observed struc-
tural maturation in the transplanted CMs. From 2 weeks to
3 months, human cardiomyocyte diameter increased from
5.92 ± 1.1 to 10.9 ± 1.8 μm, equivalent to the size of adult
monkey cardiomyocytes and only slightly smaller than adult
human cardiomyocytes (Hoshino et al., 1983). The graft
cardiomyocytes showed increased alignment of their con-
tractile cytoskeletons, elongated to typical rod shape, and
showed polarized expression of the gap junction protein,
connexin43, and the adherens junction protein, N-cadherin,
at intercalated disks by 3 months (Fig. 2). Thus, hESC-derived
cardiomyocytes appear capable of developing to an adult
phenotype in the proper environment. We speculate that this
maturation will increase functional improvements.
Electromechanical integration of stem cell derived
cardiomyocyte grafts
Studies from multiple groups have demonstrated effective
engraftment of hESC-CM and positive functional effects on
the infarcted heart. However, until recently the mechanismme after delivery into the host heart. Confocal immunofluores-
ocytes delivered into the infarcted monkey heart. Comparison is
F) after cell delivery. Human cardiomyocytes display increased
d increased cadherin expression (E–F) with time. GFP = green
660 J.J.H. Chong, C.E. Murryunderpinning the functional improvements was unknown.
Although it appears intuitive that functional hPSC-CMs should
electromechanically couple to the host heart after trans-
plantation, this had not been conclusively demonstrated.
Early studies indirectly supported the coupling of ESC-CM to
the host heart (Gepstein et al., 2010; Kehat et al., 2004; Xue
et al., 2005). Recently, together with the laboratory of
Michael Laflamme, we used a guinea-pig model of MI to
show that hESC-CM can electromechanically couple to the
injured host heart (Shiba et al., 2012). In these experiments
a line of hESC-CM expressing a calcium indicator protein,
GCAMP3, was created using zinc-finger nuclease technology.
These CMs flash green fluorescence with each calcium
transient, allowing the identification of every contraction of
human CM graft within the guinea pig heart. By correlating the
fluorescence transients with the host electrocardiogram
(measuring depolarization over the whole heart) we showed
that most hESC-CM grafts were electromechanically coupled
to the host. Although this does not exclude cardiac functional
improvement due to other paracrine effects (by which various
ASCs exert their functional benefits), the proof that hESC-CM
acts functionally and synchronously with hearts in which they
were transplanted was a major step forward for the field.
In our recent NHP study, we again used the same GCAMP3
expressing hESC-CM cell line and adapted the Langendorff ex
vivo perfusion model for the large animal heart. While some
hESC-CM grafts in the guinea pig model did not demonstrate
electromechanical coupling, in the macaque, all identified
hESC-CM grafts were perfectly coupled to the host myocardi-
um. Reasons for the improved electromechanical integration
may relate to the difference in heart rates of these species or
the patchier infarcts caused by the ischemia–reperfusion
model in monkeys, which may give more opportunities to
couple than the confluent cryoinjuries used in guinea pigs.Figure 4 Arrhythmias occur early after engraftment of human
cardiomyocytes in the infarcted monkey heart. Monkeys treated
with human embryonic stem cell derived cardiomyocytes (hESC-CM)
had telemetric electrocardiographic monitoring devices implanted
before myocardial infarction. Electrocardiogram traces are shown
from the same animal after engraftment of hESC-CM. Sinus rhythm
(A) was seen during continuous telemetric recordings before
and after myocardial infarction. Early after hESC-CM engraftment
non-sustained (duration greater than 3 beats but less than 30 s,
B–C) and sustained (duration greater than 30 s, D–E) ventricular
arrhythmias were observed. Note the different rates. Ventricular
tachycardia was defined as a ventricular rhythm with rate of more
than 180 beats/min. Slower ventricular rhythms were defined as
accelerated idioventricular rhythms. Arrow in (D) shows fusion
beat and double arrow in (E) shows capture beat both of which
demonstrate atrioventricular dissociation proving the ventricular
origin of the wide-QRS complex rhythm.Arrhythmogenesis
Early clinical studies using skeletal myoblasts for cardiac
regeneration/repair were complicated by ventricular arrhyth-
mias in cell-treated subjects (Menasche et al., 2003;
Siminiak et al., 2004; Smits et al., 2003). These findings,
together with the failure of myoblasts to improve systolic
function, led to a rapid decline in interest for these cells.
Although arrhythmogenesis was a highly feared possible
complication of the later trials using BM derived mononu-
clear cells or MSCs (Assmus et al., 2002; Hare et al., 2009;
Heldman et al., 2013; Hendrikx et al., 2006; Perin et al.,
2003), increased frequency of ventricular arrhythmias in
treated subjects has not occurred.
The explanation for the contrasting experiences in these
clinical trials can be explained by key differences among the
ASC derivatives engrafted within recipients' hearts. Firstly,
differentiated skeletal muscle cells lack gap junctions and
therefore cannot electrically couple to the host heart into
which they are delivered (Gepstein et al., 2010; Reinecke
et al., 2000; Roell et al., 2007). Studies using programmed
electrical stimulation have demonstrated that this large
graft of uncouple cells creates a conduction block and serves as
a substrate for ventricular arrhythmias (Roell et al., 2007).
Furthermore, over-expression of connexin43, the major gap
junction protein facilitating electrical conduction betweencardiomyocytes, ameliorated this increased arrhythmogenesis.
In contrast, BM derived mononuclear cells and MSCs do not
show sustained engraftment in the host heart, so of course they
cannot leave an electrically uncoupled substrate as an
arrhythmogenic source.
PSC on the other hand, displays sustained engraftment
within infarcted hearts and is capable of spontaneous electrical
661Cardiac regeneration using pluripotent stem cells—Progression to large animal modelsactivity as well as responding to endogenous pacing. Therefore,
ventricular arrhythmias after delivery into an infarcted
ventricle have been an important and valid concern. Using
programmed electrical stimulation, we showed that hESC-CM
decreases the propensity for ventricular arrhythmias in the
guinea pig heart (Shiba et al., 2012). Since hESC-CM can
electromechanically couple to the host heart, it seems
likely that hESC-CMs create a new conduction bridge across
an otherwise electrically silent scar. This would decrease
the arrhythmogenic substrate and therefore decrease
arrhythmogenicity. Although very promising, as discussed
above, large animal models are required to confirm such
findings in structurally larger hearts that possess lower
spontaneous heart rates. This is particularly important with
respect to ventricular arrhythmias since the faster heart
rate of smaller animals may be able to “pace terminate”
re-entrant circuits or overdrive suppress ectopic pacemak-
ing. Furthermore, larger grafts required in larger hearts
may have increased arrhythmogenicity due to larger areas
of slowed wave front propagation.
In this light, it may not be surprising that our macaque
studies demonstrated transient, non-fatal ventricular ar-
rhythmias in hESC-CM treated animals (Fig. 4). In fact all
animals that received hESC-CM had sustained ventricular
arrhythmias recorded on telemetric electrocardiography. No
ventricular arrhythmias were observed in any of the “sham”
treated animals. These were most commonly a wide complex
rhythm with heart rate similar to the animal's resting heart
rate. Although atrial depolarization with slowed AV nodal
or His-Purkinje conduction can cause a wide QRS complex
rhythm on electrocardiographs, the presence of occasional
capture beats, fusion beats and sudden change of cardiac
axis all suggest that the observed rhythms were ventricular
in origin. Fortunately, the arrhythmias peaked and declined
over a 2–3 week period, and the monkey studied out to
3 months had no arrhythmias for the last 2 months. This
suggests that the grafts have a period of “growing pains”,
after which they electrically adapt to the host heart.
In general terms, arrhythmias can result from enhanced
automaticity or from re-entrant mechanisms. Enhanced
automaticity, in turn, can result from ectopic pacemaking
or from triggered activity, e.g. due to early or delayed
after-depolarizations. At present we do not know which of
these mechanisms underlies arrhythmias in our monkeys, or
whether different mechanisms may underlie the ventricular
tachycardia vs. the idioventricular rhythm. The cardiomyocytes
transplanted have automaticity in culture due to pacemaking
currents (Laflamme et al., 2005; Zhu et al., 2009) and others
have reported after-depolarizations in these cells due to low
expression of the iK1 channel (Lieu et al., 2013). Our initial
experiments in optical mapping suggest that the human
cardiac grafts have slower conduction than the surrounding
host myocardium (Shiba et al., 2012), and this could
predispose to unidirectional block and re-entry. Studies
are underway to sort these possibilities out. All of these
pro-arrhythmic properties are related to the immature state
of differentiation that these cardiomyocytes show (Yang
et al., 2014). If their maturation could be advanced prior to
transplantation, it is possible that the arrhythmias would be
reduced or disappear.
Why is it that arrhythmias were seen in the monkey heart,
when an anti-arrhythmic effect was seen in the guinea pig?The same hESC-CM cell lines and differentiation protocols
were used for both, and comparable CM purities were
achieved. Therefore, the difference is unlikely to be due
to the cells delivered. A more likely explanation is that
differences in the host hearts of the respective species were
the cause. In this regard, there are three likely possibilities
1) method of myocardial infarct creation, 2) resting heart
rate, and 3) size of the host heart.
With respect to all of the three points, there are important
implications for future treatment of human patients. Firstly,
myocardial injury caused by cryo-injury (guinea pig model)
may affect electrophysiological properties of the infarcted
heart in a different manner to ischemia–reperfusion (monkey
model). Myocardial infarcts suffered by human patients are
mechanistically different from both of these models. Myocar-
dial infarction resulting from ruptured atherosclerotic plaques
will have systemic and microvascular effects not present in
these animal models and these effects may have subsequent
influences on any resulting arrhythmias. Secondly, the resting
heart rate of humans is approximately 70 bpm, almost half
of the pig tailed macaque heart rate. Finally, while the
macaque hearts were much larger than guinea-pig hearts of
the prior study, they are 10 times smaller than the average
adult human heart. For all of these reasons ventricular
arrhythmias may be increased if the same approach used in the
experimental animals is used in clinical practice. Therefore,
further assessment of the resulting arrhythmias is required.Next steps for cardiac repair with pluripotent stem
cell derived cardiomyocytes
The study of hESC-CM remuscularization of the NHP heart
discussed above has advanced the translational progress of
hESC-CM in several ways. Firstly, these experiments have
shown that clinical scale production of hESC-CM is possible
and viable. While many groups have demonstrated efficient
differentiation of relatively pure CMs from hESC and advanced
differentiation methods with use of small molecules alone
(without need of human cytokines), our NHP experiments
are the first to produce, cryopreserve and deliver 1 billion
hESC-CMs to the infarcted heart of any large animal. Future
improvements will be required in terms of further increasing
the scale of hESC-CM production. Increased use of bioreactors
and automated technologies will be a useful tool in developing
reproducible clinical grade hESC-CM batches. Together these
advances will ultimately lead to a decrease in cost that will
enable a viable model of clinical scale hESC-CM production for
future human trials.
Secondly, these studies have shown that hESC-CMs can
engraft and remuscularize large areas of infarcted myocar-
dium. This had not been demonstrated previously (as
discussed above). It is true that intense immune suppression
was required in this xenogenic model to achieve the high
degree of engraftment. Next steps will require finding a
lower threshold of immune suppression that will still
support significant engraftment. Clinical hematology and
solid-organ transplantation programs have added to our
immunological understanding of graft–host interactions.
Having an allogeneic model for cell therapy, as opposed to a
xenogeneic model, would allow us to study the immune
response more meaningfully. We are optimistic that low
662 J.J.H. Chong, C.E. Murrydose immune suppression or potentially graft tolerance
induction will enable hESC-CM replacement therapy with-
out the side effects of long term immune suppression used
for current cadaveric heart transplants.
Finally, the most important next steps required will be to
thoroughly investigate the mechanism of the arrhythmias
observed in our NHP studies. While the results appear at first
glance to indicate a formidable barrier impeding clinical
translation, we do not feel that this barrier is insurmount-
able. Firstly, we have shown that the ventricular arrhyth-
mias appear to be transient, with a reduction in frequency
after 2 weeks from engraftment. Preliminary analysis also
suggests a cellular adaptation occurring during this 2 week
period with an up regulation of crucial intercellular proteins
including cadherins and gap junction proteins. Furthermore,
clinical cardiology has already given us a number of tools with
which to deal with ventricular arrhythmias. These methods
may differ depending on the underlying mechanisms but could
include altering the host arrhythmogenic substrate by radio-
frequency ablation, placement of implantable cardioverter
defibrillators or altering the hESC-CM to be delivered (e.g. in
vitro maturation).
It is an exciting period in the history of cardiac regenerative
cell therapies with a new chapter heralding the eminent
utilization of PSCs as cardiomyocyte replacement therapy.Acknowledgments
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